What’s new
Whether clinicians are specifically disclosing the risk of ADE to COVID-19 vaccine recipients in clinical trials, which portends the standard of care after vaccine approval, is unknown. Whether ADE will and has been occurring in COVID-19 remains unproven. This review reveals that the probability that ADE is occurring or will occur in COVID-19 and vaccine recipients is high enough to be significant, requiring disclosure as a specific risk in informed consents for COVID-19 vaccines.